Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

Delayed Quote. Delayed Nasdaq - 11/26 04:00:00 pm
89.38 USD   -0.08%
4d agoDJU.S. Stocks Close Higher
4d ago S&P 500 ticks up to record on central bank bets
4d agoDJU.S. Stocks Pare Gains
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioMarin Pharmaceutical In
Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions

BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.

The company operates its business through one segment, the biopharmaceutical development and commercialization segment.

Its company's product portfolio is comprised of five approved products and multiple investigational product candidates which include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.

Naglazyme is a recombinant form of N-acetylgalactosamine 4-sulfatase indicated for patients with ucopolysaccharidosis VI. MPS VI is a debilitating life-threatening genetic disease for which no other drug treatment currently exists and is caused by the deficiency of arylsulfatase B, an enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans, or GAGs.

Kuvan is a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase, indicated for patients with PKU, which is an inherited metabolic disease that affects patients under the age of 40 in the developed world.

Aldurazyme has been approved for marketing in the U.S., EU and other countries for patients with mucopolysaccharidosis.

Firdapse is a form of 3, 4-diaminopyridine for the treatment of Lambert Myasthenic Syndrome.

And VIMIZIM is an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder.

The company was founded on March 21, 1997 and is headquartered in Novato, CA.

Number of employees : 1 341 persons.
Sales per Businesses
20122013Delta
USD (in Million)%USD (in Million)%
Biopharmaceutical Development and Commercialization500.72101.2%548.49100% +8.71%
Sales per Regions
20122013Delta
USD (in Million)%USD (in Million)%
United States249.7550.5%277.5050.6% +10%
Europe108.1421.9%116.9021.3% +7.49%
Latin America74.3915%67.3412.3% -10.47%
Rest of the World64.2213%76.6314% +16.19%
International-----
Managers
NameAgeSinceTitle
Jean-Jacques Bienaimé, MBA602005Chief Executive Officer & Director
Pierre LaPalme732004Chairman
Daniel K. Spiegelman, MBA552012Chief Financial Officer & Executive Vice President
Robert A. Baffi PhD, MBA592000Executive Vice President-Technical Operations
Gordon Vehar, PhD-2008Vice President-Research
Henry J. Fuchs, MD562009Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux, MBA-2008Chief Information Officer & Vice President
Elaine J. Heron PhD, MBA662002Independent Non-Executive Director
Mike G. Grey612005Independent Non-Executive Director
Richard A. Meier542006Independent Non-Executive Director
Shareholders
NameShares%
Capital Research & Management Co. (Global Investors) 17,876,01312.2%
Sands Capital Management LLC 11,925,2488.11%
Fidelity Management & Research Co. 8,262,7925.62%
The Vanguard Group, Inc. 8,226,7015.59%
PRIMECAP Management Co. 8,064,2195.48%
BlackRock Fund Advisors 6,465,1674.39%
Jennison Associates LLC 5,965,8884.06%
SSgA Funds Management, Inc. 4,318,0812.94%
Wells Capital Management, Inc. 2,576,5811.75%
T. Rowe Price Associates, Inc. 2,153,5251.46%
Holdings
NameShares%Valuation
Catalyst Pharmaceutical Partners, Inc. (CPRX) 6,666,6679.93%22,133,334 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
SUN PHARMACEUTICA..
OTSUKA HOLDINGS C..
ASPEN PHARMACARE ..
BIOMARIN PHARMACE..
ENDO INTERNATIONA..
HOSPIRA, INC.
ONO PHARMACEUTICA..
CIPLA LTD
SIHUAN PHARMACEUT..
SHANGHAI FOSUN PH..
TAISHO PHARMACEUT..
CADILA HEALTHCARE..
LUYE PHARMA GROUP..
-
CHINA MEDICAL SYS..
SHENZHEN SALUBRIS..
SICHUAN KELUN PHA..
-
DIVI'S LABORATORI..
SHENZHEN HEPALINK..
-
GLENMARK PHARMACE..
XIZANG HAISCO PHA..
Sector Pharmaceuticals
Company contact information
BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, CA 94901

Phone : +1.415.506.6700
Web : www.bmrn.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF